1) Ali MK, Lam RW:Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatry Dis Treat 7:39-49, 2011
2) Faravelli C, Cosci F, Ciampelli M, et al:A self-controlled, naturalistic stuy of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother Psychosom 72:95-101, 2003
3) Fraguas R, da Silva Telles RM, Alves TC, et al:A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure:The relevance of the placebo effect and psychological symptoms. Contemp Clin trials 30:205-211, 2009
4) Gottlieb SS, Kop WJ, Thomas SA, et al:A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heat J 153:868-873, 2007
5) Haeusler JM:Change in formulation and its potential clinical and pharmacoeconomic value:Example of extended release venlafaxine. Curr Med Res Opin 25:1089-1094, 2009
6) Lydiard RB, Stahl SM, Hertzman M, et al:A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 58:484-491,1997
7) Möller HJ, Schnitker J, Flürenbrock W, et al:Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. Pharmacopsychiatry 43:210-215, 2010
8) Mottram P, Wilson K, Strobl J:Antidepressants for depressed elderly. Cochrane Database Syst Rev(1), 2006
9) Myers ED, Calvert EJ:Information, compliance and side-effects:A study of patients on antidepressant medication. Br J ClinPharmacol 17:21-25, 1984
10) 野崎剛弘,吉村隆之,菅原英世,他:心療内科を受診したうつ病患者のプロスペクティブ・スタディ(第1報)―病型と治療成績との関係.心身医学42:575-584, 2002
11) Pitchot W, Scantamburlo G, Ansseau M:Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine. Psychiatr Danub 1(Supple):S106-S107, 2010
12) Pizzi C, Rutjes AW, Costa GM, et al:Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 107:972-979, 2011
13) Rapaport MH, Lydiard RB, Pitts CD, et al:Low doses of controlled-release paroxetine in the treatment of late-life depression:A randomized, placebo-controlled trial. J Clin Psychiatry 70:46-57, 2009
14) Sheehan DV, Keene MS, Eaddy M, et al:Differences in medication adherence and healthcare resource utilization patterns:Older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22:963-973, 2008
15) 上垣淳,高橋幸男,山根巨州,他:外来通院患者に対するSNRI(milnacipran)の使用経験の検討―精神科クリニックにおける治療経過から.臨精薬理 5(増刊):175-184, 2002